Drugs / CTL
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04567069 | Sep 2020 → Dec 2021 | gastric cancer | The Second Hospital of Shandong University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04567069 ↗ |
| Modality | Cell therapy | “Cytotoxic lymphocytes are CD3+ T cells co-cultured with DCs.” NCT04567069 ↗ |
| Route | Intravenous | “Four intravenous (iv) drip injections of CTL will be given at days 7, 9, 27, 29; 1-2×109 cells/time.” NCT04567069 ↗ |